The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Home » For Researchers » About our Research » Funding Opportunities
NETRF offers three different neuroendocrine cancer research grants (Investigator, Pilot, and Mentored Awards) with cancer research grants ranging from $90,000 to $270,000.
We invite innovative and transformative research proposals in NETs to help bring the field closer to more effective therapies. We are equally interested in basic, translational and clinical research applications, and encourage collaborations between investigators with expertise in different fields.
We are very interested in grant proposals from multidisciplinary groups comprised of basic scientists, clinicians, and experts across relevant cutting-edge disciplines. Proposals that cover promising and potentially transferable strategies and/or technologies, which have been applied successfully to other areas of cancer research, are highly encouraged and will be evaluated based on their level of applicability to NETs.
Some areas of interest include but not limited to:
We invite also proposals that cover promising and potentially transferable technologies, which have been applied successfully to other areas of cancer.
While we recognize that neuroendocrine cancers can develop in many different organs, our focus includes:
We continue to have an interest and fund applications proposing to study all aspects of gastro-entero-pancreatic NETs.
We are interested in funding work in well-differentiated, low-grade typical carcinoids (TCs), well-differentiated, intermediate-grade atypical carcinoids (ACs), or diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH).
Currently, the lung fund does not extend to SCLC, LCLC, non-SCLC, squamous cell carcinomas, adenocarcinomas, mesotheliomas or poorly differentiated non–small cell lung carcinomas.
Prior research in NETs is not a prerequisite. We encourage expert cancer scientists to enter the NET research field. However, such candidates must demonstrate a commitment to continue with NET research.
See our FAQ for more information.